Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

Merck updates on Phase 3 Keynote-412 trial in advanced head and neck squamous cell carcinoma

Merck and Orion collaborate for the development and commercialization of ODM-208

Orion to receive an upfront payment of USD 290 million

Enveda appoints Vanitha Sekar as Chief Business Officer

She joins Enveda from Gilead Sciences

Lynparza gets positive opinion from EU CHMP as adjuvant treatment for germline BRCA-mutated early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival in patients

Merck presents positive results from phase 1/2 study evaluating V116

V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019

AstraZeneca and Merck announces results from phase 3 PROpel trial of Lynparza

LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)

FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer

Acceptance based on results from the phase 3 KEYNOTE-091 trial

Merck and Ridgeback announce new data for investigational molnupiravir

Based on a post hoc analysis, fewer required respiratory interventions